PLA Code Application Filed for inFoods IBS Test — A Key Step Toward Reimbursement

Core Insights - Biomerica, Inc. has submitted an application for a Proprietary Laboratory Analysis (PLA) code for its inFoods IBS diagnostic test, aiming to enhance patient access and insurance reimbursement for the test [1][2][3] Group 1: Product and Market Overview - The inFoods IBS test identifies patient-specific foods that trigger IBS symptoms such as bloating, abdominal pain, diarrhea, and constipation, providing a personalized approach to treatment [1][3] - IBS affects approximately 10% to 15% of adults in the U.S., leading to significant healthcare costs, indicating a substantial market opportunity for effective management solutions [4] - The inFoods platform addresses an unmet need for personalized management strategies in the IBS market, differentiating itself from traditional trial-and-error diets and symptom-suppressing medications [3][4] Group 2: Clinical Validation and Adoption - A randomized clinical trial published in a leading medical journal demonstrated that patients following a personalized diet based on inFoods test results experienced significantly greater symptom relief compared to those on a placebo diet, highlighting the clinical potential of the platform [5] - Biomerica is collaborating with leading gastroenterology groups and healthcare systems to promote the adoption of the inFoods IBS test, which is also available for direct-to-consumer ordering [6] Group 3: Strategic Goals and Long-Term Vision - The application for the PLA code is part of Biomerica's broader commercialization strategy to facilitate access to the inFoods IBS test and enhance transparency in claims submission [2][3] - The company believes that insurance reimbursement, supported by clinical validation, positions inFoods IBS as a category-defining diagnostic, contributing to long-term value creation [7][8]